# A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Study · id `cardio:ct-nct07743450` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07743450](<https://clinicaltrials.gov/study/NCT07743450>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07743450

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1560 participants.

## Technical summary

Registry record NCT07743450. Randomized; triple masking; primary purpose treatment. Start 2026-08-28 (actual); primary completion 2028-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1560 participants (planned count; ClinicalTrials.gov record NCT07743450, source copy `cardio:ctgov-nct07743450-2026-09-16`, retrieved 2026-10-26)
- Started: 2026-08-28 (actual) (ClinicalTrials.gov record NCT07743450, source copy `cardio:ctgov-nct07743450-2026-09-16`, retrieved 2026-10-26)
- Primary completion: 2028-07 (anticipated) (ClinicalTrials.gov record NCT07743450, source copy `cardio:ctgov-nct07743450-2026-09-16`, retrieved 2026-10-26)
- Completion: 2028-07 (anticipated) (ClinicalTrials.gov record NCT07743450, source copy `cardio:ctgov-nct07743450-2026-09-16`, retrieved 2026-10-26)
- Countries: United States; Czechia; Germany; Greece; Poland; United Kingdom (ClinicalTrials.gov record NCT07743450, source copy `cardio:ctgov-nct07743450-2026-09-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07743450-2026-09-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- Acronym: AURORA-2
- Condition: Obesity
- Condition: Overweight
- Condition: Chronic Weight Management
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): ASC30 tablets A1
- Intervention (Drug): Placebo
- Lead sponsor: Ascletis Pharma (China) Co., Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 0a656e6b7f637799581c997833262d080f44793eb1f857a14aeadfc65aafbe5f
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
